SIETES :: 93212 citas

Resultados de la búsqueda por VÍA INTRAVENOSA REFINAR BÚSQUEDA

1.

Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M, Ahn M-Y, Nahass RG, Chen Y-S, SenGupta D, et al. for the GS-US-540-5733 Investigators. Remdesivir for 5 or 10 days in patients with severe covid-19. N Engl J Med 2020:27 de mayo. [Ref.ID 103634]

2.

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, et al. for the ACTT-1 Study Group Members. Remdesivir for the treatment of covid-19 — Preliminary report. N Engl J Med 2020:22 de mayo. [Ref.ID 103631]

3.

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, et al.. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395:29 de abril. [Ref.ID 103630]

4.

Anónimo. NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19. National Institute of Allergy and Infectious Diseases 2020:29 de abril. [Ref.ID 103612]

5.

Berghella V, Bellussi F. Antibiotics for operative vaginal delivery: practice-changing data. Lancet 2019;393:. [Ref.ID 103123]

6.

Knight M, Chiocchia V, Partlett C, Rivero-Arias O, Hua X, Hinshaw K, Tuffnell D, Linsell L, Juszczak E, on behalf of the ANODE collaborative group. Prophylactic antibiotics in the prevention of infection after operative vaginal delivery (ANODE): a multicentre randomised controlled trial. Lancet 2019;393:15 de junio. [Ref.ID 103118]

7.

Chambers HF. Omadacycline — The newest tetracycline. N Engl J Med 2019;380:7 de febrero. [Ref.ID 103037]

8.

O'Riordan W, Green S, Overcash JS, Puljiz I, Metallidis S, Gardovskis J, Garrity-Ryan L, Das AF, Tzanis E, Eckburg PB, Manley A, Villano SA, Steenbergen JN, Loh E. Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med 2019;380:7 de febrero. [Ref.ID 103036]

9.

Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med 2019;380:7 de febrero. [Ref.ID 103035]

10.

Lee-HY, Ban G-Y, Jeong C-G, Lee JH, Park SH, Kim SH, Lee Y-H, Ye Y-M. Propacetamol poses a potential harm of adverse hypotension in male and older patients. Pharmacoepidemiol Drug Saf 2017;26:256-64. [Ref.ID 102062]

11.

Anónimo. Ibalizumab shows promising results treating multi-drug-resistant HIV. DIA Daily 2016:4. [Ref.ID 100869]

12.

Wang C, Wong S, Graham DJ. Risk of anaphylaxis with intravenous iron products. JAMA 2016;315:2232-3. [Ref.ID 100367]

13.

DeLoughery TG. Risk of anaphylaxis with intravenous iron products. JAMA 2016;315:2232. [Ref.ID 100366]

14.

Pathan SA, Mitra B, Straney LD, Afzal MS, Anjum S, Shukla D, Morley K, Al Hilli SA, Al Rumaihi K, Thomas SH, Cameron PA. Delivering safe and effective analgesia for management of renal colic in the emergency department: a double-blind, multigroup, randomised controlled trial. Lancet 2016;387:1999-2007. [Ref.ID 100295]

15.

Knoedler JJ, Lieske JC. Non-steroidal anti-inflammatory drugs for renal colic. Lancet 2016;387:1971-2. [Ref.ID 100294]

16.

Jian Z, Li H, Race NS, Ma T, Jin H, Yin Z. Is the Era of intravenous proton pump inhibitors coming to an end in patients with bleeding peptic ulcers? meta-analysis of the published literature.. Br J Clin Pharmacol 2015:18 de diciembre. [Ref.ID 99821]

17.

Connors JM. Antidote for factor Xa anticoagulants. N Engl J Med 2015;373:2471-2. [Ref.ID 99801]

18.

Wang C, Graham DJ, Kane RC, Xie D, Wemecke M, Levenson M, MaCurdy TE, Houstoun M, Ryan Q, Wong S, Mott K, Sheu T-C, Limb S, Worrall C, Kelman JA, Reichman ME. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 2015;314:2062-8. [Ref.ID 99687]

19.

Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015;373:2413-24. [Ref.ID 99658]

20.

Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, Edan G, COPOUSEP investigators West Network for Excellence in Neuroscience. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet 2015;386:974-81. [Ref.ID 99529]